SureTrader
Home > Boards > US Listed > Miscellaneous > Rigel Pharmaceuticals Inc. (RIGL)

7:40AM On The Wires (WIRES) :

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 427
Posts 23,184
Boards Moderated 3
Alias Born 09/11/06
160x600 placeholder
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 2/16/2018 5:15:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2018 5:50:51 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2018 10:06:16 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2018 11:49:06 AM
Schedule 13g Edgar (US Regulatory) - 2/8/2018 12:11:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/2/2018 4:37:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/26/2018 6:45:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/26/2018 6:39:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/26/2018 6:36:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/26/2018 6:34:26 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/26/2018 6:31:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/26/2018 6:28:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/26/2018 6:24:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/26/2018 5:15:58 PM
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 1/26/2018 4:05:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/23/2018 5:33:04 PM
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 1/5/2018 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/4/2018 4:49:08 PM
Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthca... PR Newswire (US) - 1/4/2018 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/15/2017 5:03:28 PM
Rigel Announces Departure of Chief Financial Officer PR Newswire (US) - 12/15/2017 7:30:00 AM
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 12/8/2017 7:05:00 PM
Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annu... PR Newswire (US) - 12/8/2017 7:30:00 AM
Detailed Research: Economic Perspectives on TiVo, Eli Lilly, Rigel Pharmaceuticals, SpartanNash, Nustar GP, and Hornbeck Offs... GlobeNewswire Inc. - 12/4/2017 8:30:00 AM
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 11/17/2017 4:05:00 PM
surf1944   Friday, 05/06/11 09:58:11 AM
Re: surf1944 post# 130
Post # of 431 
7:40AM On The Wires (WIRES) :

Rigel Pharmaceuticals, Inc. (RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer (PFE) is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343's development to date and expects to design a Phase 2 clinical trial with R343 later this year.



surf's up......crikey



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist